Caladrius Biosciences, Inc. announced that it has treated the first patient in its Phase IIb FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction at The Christ Hospital Health Network in Cincinnati, Ohio.
[Caladrius Biosciences, Inc.]
6445212
{6445212:nan}
apa
50
1
158310
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
